METRASENS LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -13.4%

  £18,318,236 → £15,869,663

• Cash

  -76.8%

  £2,648,221 → £614,363

• Net assets

  -33.2%

  £5,478,599 → £3,658,296

• Employees

  0%

  88 → 88

• Operating profit

  +32.3%

  -£2,422,342 → -£1,638,970

• Profit before tax

  +31.2%

  -£2,530,126 → -£1,739,842

• Wages

  -5.8%

  £8,020,589 → £7,557,256

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have a reasonable expectation that the group has sufficient resources to continue in operation for the foreseeable future, being at least 12 months from the date of signing these financial statements, and that, for this reason, the directors consider the adoption of the going concern basis of accounting in preparing the financial statements is appropriate.”

Group structure

1. METRASENS LIMITED · parent
   1. Metrasens Inc 100% · USA

Significant events

• “The business undertook a cost restructuring and rationalisation during the period which resulted in the removal of £2m of recurring annual cost from the business. This activity was undertaken in the final quarter of the financial year and is therefore predominantly to the benefit of future financial periods.”
• “During the financial year we have been nearing completion of a newly developed product for application in the MRI safety market. This product has been a significant focus of product development activity during the year and is expected to be brought to market during quarter 3 of the financial year ending 30 April 2026.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

0

last 24 months

Officers appointed

3

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.